Olema Pharmaceuticals Toekomstige groei
Future criteriumcontroles 0/6
Olema Pharmaceuticals's earnings are forecast to decline at 4.9% per annum while its annual revenue is expected to grow at 72.5% per year. EPS is expected to decline by 4.6% per annum. Return on equity is forecast to be -66.6% in 3 years.
Belangrijke informatie
-4.9%
Groei van de winst
-4.6%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | 72.5% |
Toekomstig rendement op eigen vermogen | -66.6% |
Dekking van analisten | Low |
Laatst bijgewerkt | 01 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Aug 29Olema Pharmaceuticals: Still Merits A Small Holding
Jun 17Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
May 11Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
Mar 28Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Mar 04Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
Nov 09We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Jun 11Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?
Mar 01Olema Oncology grants stock options for 58.3K shares
Oct 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 13Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18
Aug 09Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype
Jul 21We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth
May 29Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 08Our Take On Olema Pharmaceuticals
Jan 05We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate
Sep 19We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth
Jun 04Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth
Feb 19Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 8 | -174 | -150 | N/A | 3 |
12/31/2025 | N/A | -155 | -137 | -144 | 5 |
12/31/2024 | N/A | -130 | -90 | -51 | 5 |
6/30/2024 | N/A | -110 | -92 | -92 | N/A |
3/31/2024 | N/A | -99 | -87 | -87 | N/A |
12/31/2023 | N/A | -97 | -84 | -84 | N/A |
9/30/2023 | N/A | -96 | -85 | -85 | N/A |
6/30/2023 | N/A | -97 | -81 | -80 | N/A |
3/31/2023 | N/A | -110 | -85 | -85 | N/A |
12/31/2022 | N/A | -105 | -82 | -82 | N/A |
9/30/2022 | N/A | -100 | -82 | -81 | N/A |
6/30/2022 | N/A | -95 | -76 | -75 | N/A |
3/31/2022 | N/A | -79 | -59 | -58 | N/A |
12/31/2021 | N/A | -71 | -52 | -51 | N/A |
9/30/2021 | N/A | -60 | -42 | -41 | N/A |
6/30/2021 | N/A | -52 | -37 | -37 | N/A |
3/31/2021 | N/A | -38 | -29 | -29 | N/A |
12/31/2020 | N/A | -24 | -20 | -20 | N/A |
9/30/2020 | N/A | -15 | -12 | -12 | N/A |
12/31/2019 | N/A | -4 | -3 | -3 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: OLMA is forecast to remain unprofitable over the next 3 years.
Winst versus markt: OLMA is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: OLMA is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: OLMA is forecast to have no revenue next year.
Hoge groei-inkomsten: OLMA is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: OLMA is forecast to be unprofitable in 3 years.